Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Leukemia

  Free Subscription


16.06.2025

1 Acta Haematol
1 Am J Hematol
4 Blood
3 Bone Marrow Transplant
1 Cancer Lett
1 Eur J Immunol
1 Exp Hematol
1 J Immunol
1 J Pediatr Hematol Oncol
3 Leuk Lymphoma
4 Leuk Res
2 N Engl J Med
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Haematol

  1. MENDEZ LM, DeAngelo DJ, Luskin MR
    Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Acta Haematol. 2025 Jun 10:1-22. doi: 10.1159/000546381.
    PubMed         Abstract available


    Am J Hematol

  2. BHATT VR, Wichman CS, Koll TT, Fisher AL, et al
    A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.
    Am J Hematol. 2025;100:1163-1172.
    PubMed         Abstract available


    Blood

  3. LUGER SM
    Introduction to a Blood Spotlight series on acute myeloid leukemia.
    Blood. 2025;145:2801-2802.
    PubMed        

  4. SELVARAJAH S, Xia D
    A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
    Blood. 2025;145:2931.
    PubMed        

  5. COURTOIS L, Pinton A, Cabannes-Hamy A, Simonin M, et al
    Surface pTalpha expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL.
    Blood. 2025;145:2903-2913.
    PubMed         Abstract available

  6. PERL AE
    Approaching a therapeutic inflection point for FLT3-mutated AML.
    Blood. 2025;145:2834-2839.
    PubMed         Abstract available


    Bone Marrow Transplant

  7. TERAMOTO M, Shimomura Y, Hosoi H, Yanada M, et al
    Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Jun 9. doi: 10.1038/s41409-025-02640.
    PubMed        

  8. KARAKUS A, Toptas T, Dal MS, Durdu A, et al
    Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias.
    Bone Marrow Transplant. 2025;60:864-872.
    PubMed         Abstract available

  9. LI L, Zhu L, Xiong M, Chen Z, et al
    Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older.
    Bone Marrow Transplant. 2025;60:773-778.
    PubMed         Abstract available


    Cancer Lett

  10. LU H, Wang H, Wang Q, Huang D, et al
    Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq.
    Cancer Lett. 2025 Jun 5:217853. doi: 10.1016/j.canlet.2025.217853.
    PubMed         Abstract available


    Eur J Immunol

  11. KATSIKI K, Tasis A, Filia A, Kotsianidis I, et al
    Comparative Analysis of the TCR Repertoire in Bone Marrow CD8(+) T Cells From Patients With Acute Myeloid Leukemia, Myelodysplastic Neoplasms, and Chronic Myelomonocytic Leukemia.
    Eur J Immunol. 2025;55:e51796.
    PubMed         Abstract available


    Exp Hematol

  12. ZHANG A, Qiu S
    Advances of RARalpha fusion genes in acute promyelocytic leukemia.
    Exp Hematol. 2025 Jun 7:104822. doi: 10.1016/j.exphem.2025.104822.
    PubMed         Abstract available


    J Immunol

  13. REN Y, Niu LT, Dong XY, Wang YQ, et al
    RGS1 is an effective T-cell marker of acute myeloid leukemia remission after hematopoietic stem cell transplantation.
    J Immunol. 2025 Jun 10:vkaf096. doi: 10.1093.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  14. KOCA YOZGAT A, Kilcik RD, Cetin S, Altintas B, et al
    Critical Complication in Childhood Leukemia: Neutropenic Enterocolitis, Risk Factors, and Outcomes.
    J Pediatr Hematol Oncol. 2025 Jun 9. doi: 10.1097/MPH.0000000000003064.
    PubMed         Abstract available


    Leuk Lymphoma

  15. LAI CE, Leahy TP, Turner AJ, Thomassen A, et al
    Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control
    Leuk Lymphoma. 2025 Jun 13:1-12. doi: 10.1080/10428194.2025.2514894.
    PubMed         Abstract available

  16. SMITH CIE
    Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C.
    Leuk Lymphoma. 2025 Jun 12:1-2. doi: 10.1080/10428194.2025.2518433.
    PubMed        

  17. DAMPMANN M, von Tresckow B, Reinhardt HC, Kuppers R, et al
    Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor.
    Leuk Lymphoma. 2025 Jun 10:1-10. doi: 10.1080/10428194.2025.2513005.
    PubMed         Abstract available


    Leuk Res

  18. KATO T, Imaizumi Y, Miyazaki Y
    Treatment strategy for indolent adult T-cell leukemia-lymphoma.
    Leuk Res. 2025;155:107714.
    PubMed         Abstract available

  19. WANG H, Han C, Gong B, Liu Y, et al
    Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts.
    Leuk Res. 2025;155:107733.
    PubMed         Abstract available

  20. AMIN MK, Khan MA, Khan FH, Zakir A, et al
    Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis.
    Leuk Res. 2025;155:107724.
    PubMed         Abstract available

  21. STEINER L, Kaur N, Jann JC, Fabarius A, et al
    Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival.
    Leuk Res. 2025;154:107718.
    PubMed         Abstract available


    N Engl J Med

  22. GUPTA S, Rau RE, Loh ML
    Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply.
    N Engl J Med. 2025;392:2286-2287.
    PubMed        

  23. HODDER A, Vora A, Samarasinghe S
    Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia.
    N Engl J Med. 2025;392:2286.
    PubMed        


    PLoS One

  24. HOSSEN MA, Jahan UMS, Hossain MA, Asif KH, et al
    Computational investigation unveils pathogenic LIG3 non-synonymous mutations and therapeutic targets in acute myeloid leukemia.
    PLoS One. 2025;20:e0320550.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  25. MOBACH S, Bergkamp ND, Ma Z, Haselager MV, et al
    Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.
    Proc Natl Acad Sci U S A. 2025;122:e2424186122.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.